Login to Your Account

Other News To Note

Wednesday, November 23, 2011
• MabCure Inc., of New York, said it signed a license agreement with Biotech Investment Corp., a Nevada-based biotech investment company, for exclusive, worldwide rights to certain MabCure hybridoma clones producing antibodies against prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription